Physician profile
Igal Staw
NPI 1013901602
$4,581.79
in general payments reported to CMS, 2019-2025
37 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.39 · 2020: $75.13 · 2021: $253 · 2022: $432 · 2023: $1,274 · 2024: $1,268 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,748.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $898.67 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $561.99 | 2022-2025 | Xifaxan, Trulance |
| Abbvie INC. | $519.24 | 2021-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $327.45 | 2020-2025 | Airsupra, Farxiga, Fasenra |
| Amneal Pharmaceuticals LLC | $194.22 | 2023 | Lyvispah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.92 | 2019-2025 | Jardiance, Ofev |
| Sumitomo Pharma America, INC. | $180.88 | 2023-2025 | Gemtesa |
| Aimmune Therapeutics, INC. | $160.56 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $152.44 | 2022-2024 | Linzess |
| Pfizer INC. | $144.77 | 2024-2025 | |
| Csl Behring | $131.93 | 2022-2024 | Hizentra |
| Exact Sciences Corporation | $130.73 | 2023-2024 | Cologuard Collection Kit |
| Ardelyx, INC. | $120.09 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $118.13 | 2023-2025 | Jardiance, Emgality, Zepbound |
| Harmony Biosciences LLC | $63.49 | 2022-2023 | Wakix |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igal Staw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.